Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men
Authors:
- 7 September 2012
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 20 (2) , 193-201
Abstract
Objectives: To examine the efficacy and safety of tadalafil in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Methods: Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia were randomized to once‐daily placebo (n = 154), tadalafil 2.5 mg (n = 151), tadalafil 5.0 mg (n = 155) or tamsulosin 0.2 mg (active control, n = 152) for 12 weeks.Results: Total International Prostate Symptom Score least‐squares mean changes from baseline to end‐point significantly improved with tadalafil 2.5 mg (−4.8, P = 0.003) and 5 mg (−4.7, P = 0.004) versus placebo (−3.0). Significant improvement in the International Prostate Symptom Score versus placebo was observed earlier (week 2) for tadalafil 5.0 mg than for tadalafil 2.5 mg (week 8). Significant improvements (P < 0.05) in both tadalafil groups versus placebo were observed for the International Prostate Symptom Score voiding subscore, International Prostate Symptom Score Quality of Life, and for Patient and Clinician Global Impressions of Improvement. Significant improvements versus placebo were observed in the International Prostate Symptom Score storage subscore for tadalafil 5.0 mg (−1.7, P = 0.021), but not tadalafil 2.5 mg (−1.5, P = 0.072). No significant improvements in benign prostatic hyperplasia Impact Index or improvements in peak urinary flow rates were observed with tadalafil 2.5 mg or 5.0 mg versus placebo. Tamsulosin treatment resulted in significant improvements versus placebo across all efficacy parameters, except for peak urinary flow rates. Safety results were consistent with the known tadalafil and tamsulosin safety profiles.Conclusions: Tadalafil once daily represents an effective and well tolerated medical treatment for Asian men presenting with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Keywords
This publication has 20 references indexed in Scilit:
- Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- Tadalafil Administered Once Daily for Treatment of Lower Urinary Tract Symptoms in Korean men with Benign Prostatic Hyperplasia: Results from a Placebo‐Controlled Pilot Study Using Tamsulosin as an Active ControlLUTS: Lower Urinary Tract Symptoms, 2011
- Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of actionNeurourology and Urodynamics, 2011
- Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1‐year, open‐label extension studyBJU International, 2011
- Clinical guideline for male lower urinary tract symptomsInternational Journal of Urology, 2009
- Erectile Dysfunction and Comorbidities in Aging Men: An Urban Cross-Sectional Study in MalaysiaThe Journal of Sexual Medicine, 2008
- Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2007
- Silodosin, a new α 1A ‐adrenoceptor‐selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo‐controlled, double‐blind study in Japanese menBJU International, 2006
- Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countriesBJU International, 2005
- Prevalence of Prostatism in Japanese Men in a Community-based Study with Comparison to a Similar American StudyJournal of Urology, 1995